The Radiation Therapy Oncology Group (RTOG) has begun a phase II study to evaluate the best treatment strategies for patients with low-risk, low-grade glioma (LGG) brain tumors.
The study, RTOG 0925, will seek to determine if neurocognitive changes caused by tumor progression can be used to help guide treatment decisions, according to the group. Led by principal investigator Dr. Ali Choucair, from the Brain Tumor Center at the Norton Neuroscience Institute, the trial will enroll 170 study participants with newly diagnosed LGG who are undergoing observation alone for clinical care.
The study will compare neurocognitive function (NCF) scores, quality of life, and seizure control over time in patients who have evidence of tumor progression with patients who have no evidence of progression.
More information can be found here.
